Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10332281 | 0.85 | L3MBTL1 (0.43) | KDM4EKMT2AL3MBTL1 | |
| SCHEMBL4564262 | 0.83 | L3MBTL1 (0.59) | L3MBTL1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL10282273 | 0.81 | LMNA (0.62) | KDM4EKMT2AL3MBTL1RAB9AALDH1A1 | |
| SCHEMBL31185802 | 0.80 | CYP1A2 (0.60) | KDM4EKMT2AL3MBTL1RAB9AALDH1A1 | |
| SCHEMBL31186198 | 0.80 | CYP1A2 (0.50) | LOXL2KDM4EKMT2AALDH1A1LMNA | |
| SCHEMBL5638909 | 0.80 | EPHX2 (0.57) | KMT2ARAB9AALDH1A1POLB | |
| SCHEMBL31185928 | 0.80 | NPC1 (0.54) | KDM4EKMT2AL3MBTL1RAB9AALDH1A1 | |
| SCHEMBL2477903 | 0.79 | KDM4E (0.56) | KDM4EKMT2AL3MBTL1RAB9AALDH1A1 | |
| SCHEMBL9728995 | 0.79 | MAPK1 (0.46) | L3MBTL1RAB9AALDH1A1POLB | |
| SCHEMBL31185896 | 0.78 | NPC1 (0.67) | L3MBTL1RAB9AALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105153146-A | Novel 3-hydroxyisothiazole 1-oxide derivative | MOCHIDA PHARM CO LTD | 2015-12-16 | — | — | CN | disclosed |
| CN-103517898-B | Novel 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO.,LTD. (JP) | 2015-09-30 | — | — | CN | disclosed |
| EP-2150539-B1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-12-18 | — | — | EP | disclosed |
| US-8367668-B2 | Pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-02-05 | — | — | US | disclosed |
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-07-15 | — | — | US | disclosed |
| EP-2150539-A1 | PYRIDAZINONE DERIVATIVES | Merck Patent GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008145243-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MET, ERBB2, RET | LOXL2 1659/4885KDM4E 1409/4885KMT2A 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.